# GLP-1 Drugs Linked to Improved Survival After Liver Transplant Retrospective study shows significant mortality reduction in liver transplant recipients using GLP-1 receptor agonists. - **Source:** [MedPage Today](https://www.medpagetoday.com) - **Published:** 2026-11-11 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/38077e56-bc1a-49ea-91c8-ed20a1870727 ## Significant Mortality Risk Reduction A retrospective study involving 2,402 liver transplant patients revealed that those using GLP-1 receptor agonists experienced a 45% lower risk of death. This protective effect was observed over a median follow-up period of 3.9 years. These findings were further validated in an independent replication cohort of 1,443 additional transplant recipients. ## Study Methodology and Demographics Researchers analyzed patients who underwent liver transplants between 2015 and 2025 at three Mayo Clinic sites. The median patient age was 61.2 years, with 65.4% being male. Most participants presented with pre-existing metabolic risk factors, including type 2 diabetes, hypertension, or a body mass index of at least 30 kg/m2. ## Metabolic Improvements Observed Patients taking GLP-1 drugs showed measurable health improvements, including a 14.2% reduction in LDL cholesterol and an 8.3% drop in total cholesterol. Additionally, HbA1c levels declined by 2.6%, and body weight decreased by 5% within two years of initiating therapy. These metabolic shifts occurred despite the relatively short median treatment duration. ## Mechanism of Survival Benefit While the exact cause of the mortality reduction remains unclear, researchers noted that GLP-1 users were less likely to die from non-liver causes. These include cardiovascular events, malignancies, infections, and graft failure. Interestingly, the survival advantage persisted regardless of whether the patient had type 2 diabetes, though it was more pronounced otherwise. ## Cardiovascular and Kidney Outcomes The study did not find a statistically significant reduction in major adverse cardiovascular events or myocardial infarction among GLP-1 users. Similarly, while trends favored GLP-1 use regarding kidney health, the difference in preventing sustained estimated glomerular filtration rate decline just missed statistical significance with a P-value of 0.06 in the analysis. ## Clinical Context of MASLD Metabolic dysfunction-associated steatotic liver disease is becoming the leading cause for liver transplants in the United States. Although the transplant procedure addresses the primary liver disease, it does not eliminate the patient's underlying metabolic risks. GLP-1 agonists are increasingly explored for their potential to manage these persistent systemic health challenges. ## Study Limitations and Constraints The research faced limitations, including a lack of statistical power to detect specific differences in major adverse cardiovascular or kidney events. Furthermore, the cause of death remained unknown for 23% of the patient population. Dr. Zhihao Li also noted that sicker transplant recipients were less frequently prescribed these specific medications. ## Future Clinical Implications These findings suggest that GLP-1 receptor agonists could play a vital role in post-transplant care by mitigating non-liver-related mortality. As metabolic diseases continue to drive transplant demand, integrating these therapies may improve long-term outcomes. Further prospective research is required to confirm these benefits and clarify the underlying biological protective pathways. ## Sources covering this story - https://www.medpagetoday.com/meetingcoverage/aasld/123845 — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._